Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma

Lee, YJ; Moon, JH; Sohn, SK; Kim, SJ; Jung, SH; Lee, JJ; Jo, JC; Shin, HJ; Lee, WS; Lee, JH; Bae, SH; Kim, MK; Lee, HS; Kim, K; Min, CK

Kim, K (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Hematol Oncol, Seoul, South Korea.; Min, CK (reprint author), Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Hematol, Seoul, South Korea.

BONE MARROW TRANSPLANTATION, 2019; 54 (12): 2051

Abstract

Bortezomib/thalidomide/dexamethasone (VTD) induction therapy followed by autologous stem cell transplantation (ASCT) is one of the standard therapies ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索